SEARCH

SEARCH BY CITATION

References

  • Barrette, R. W., S. A. Metwally, J. M. Rowland, L. Xu, S. R. Zaki, S. T. Nichol, P. E. Rollin, J. S. Towner, W. J. Shieh, B. Batten, T. K. Sealy, C. Carrillo, K. E. Moran, A. J. Bracht, G. A. Mayr, M. Sirios-Cruz, D. P. Catbagan, E. A. Lautner, T. G. Ksiazek, W. R. White, and M. T. McIntosh, 2009: Discovery of swine as a host for the Reston ebolavirus. Science 325, 204206.
  • Basler, C. F., X. Wang, E. Mühlberger, V. Volchkov, J. Paragas, H. D. Klenk, A. García-Sastre, and P. Palese, 2000: The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. U.S.A. 97, 1228912294.
  • Basler, C. F., A. Mikulasova, L. Martínez-Sobrido, J. Paragas, E. Mühlberger, M. Bray, H. D. Klenk, P. Palese, and A. García-Sastre, 2003: The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77, 79457956.
  • Baum, A., and A. García-Sastre, 2010: Induction of type I interferon by RNA viruses: cellular receptors and their substrates. Amino Acids 38, 12831299.
  • Baum, A., and A. García-Sastre, 2011: Differential recognition of viral RNA by RIG-I. Virulence 2, 166169.
  • Bavari, S., C. M. Bosio, E. Wiegand, G. Ruthel, A. B. Will, T. W. Geisbert, M. Hevey, C. Schmaljohn, A. Schmaljohn, and M. J. Aman, 2002: Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195, 593602.
  • Bivalkar-Mehla, S., J. Vakharia, R. Mehla, M. Abreha, J. R. Kanwar, A. Tikoo, and A. Chauhan, 2011: Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system. Virus Res. 155, 19.
  • Brass, A. L., I. C. Huang, Y. Benita, S. P. John, M. N. Krishnan, E. M. Feeley, B. J. Ryan, J. L. Weyer, W. L. van der, E. Fikrig, D. J. Adams, R. J. Xavier, M. Farzan, and S. J. Elledge, 2009: The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139, 12431254.
  • Bray, M., 2001: The role of the Type I interferon response in the resistance of mice to filovirus infection. J. Gen. Virol. 82, 13651373.
  • Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins, 1998: A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178, 651661.
  • Cárdenas, W. B., Y. M. Loo, M. Gale Jr, A. L. Hartman, C. R. Kimberlin, L. Martínez-Sobrido, E. O. Saphire, and C. F. Basler, 2006: Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80, 51685178.
  • Carette, J. E., M. Raaben, A. C. Wong, A. S. Herbert, G. Obernosterer, N. Mulherkar, A. I. Kuehne, P. J. Kranzusch, A. M. Griffin, G. Ruthel, P. Dal Cin, J. M. Dye, S. P. Whelan, K. Chandran, and T. R. Brummelkamp, 2011: Ebola virus entry requires the cholesterol transporter Niemann-Pick C1. Nature, 477, 340343.
  • Cen, S., Z. G. Peng, X. Y. Li, Z. R. Li, J. Ma, Y. M. Wang, B. Fan, X. F. You, Y. P. Wang, F. Liu, R. G. Shao, L. X. Zhao, L. Yu, and J. D. Jiang, 2010: Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 285, 1654616552.
  • Chandran, K., N. J. Sullivan, U. Felbor, S. P. Whelan, and J. M. Cunningham, 2005: Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science 308, 16431645.
  • Chang, T. H., T. Kubota, M. Matsuoka, S. Jones, S. B. Bradfute, M. Bray, and K. Ozato, 2009: Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog. 5, e1000493.
  • Côté, M., J. Misasi, T. Ren, A. Bruchez, K. Lee, C. M. Filone, L. Hensley, Q. Li, D. Ory, K. Chandran, and J. Cunningham, 2011: Small molecule inhibitors reveal Niemann-Pick C1 is essential for Ebola virus infection. Nature 477, 344348.
  • Dolnik, O., V. Volchkova, W. Garten, C. Carbonnelle, S. Becker, J. Kahnt, U. Ströher, H. D. Klenk, and V. Volchkov, 2004: Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J. 23, 21752184.
  • Dolnik, O., L. Kolesnikova, and S. Becker, 2008: Filoviruses: interactions with the host cell. Cell. Mol. Life Sci. 65, 756776.
  • Donelan, N. R., C. F. Basler, and A. García-Sastre, 2003: A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J. Virol. 77, 1325713266.
  • Douglas, J. L., K. Viswanathan, M. N. McCarroll, J. K. Gustin, K. Früh, and A. V. Moses, 2009: Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. J. Virol. 83, 79317947.
  • Dubé, M., B. B. Roy, P. Guiot-Guillain, J. Binette, J. Mercier, A. Chiasson, and E. A. Cohen, 2010: Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 6, e1000856.
  • Ebihara, H., A. Takada, D. Kobasa, S. Jones, G. Neumann, S. Theriault, M. Bray, H. Feldmann, and Y. Kawaoka, 2006: Molecular determinants of Ebola virus virulence in mice. PLoS Pathog. 2, e73.
  • Enterlein, S., K. L. Warfield, D. L. Swenson, D. A. Stein, J. L. Smith, C. S. Gamble, A. D. Kroeker, P. L. Iversen, S. Bavari, and E. Mühlberger, 2006: VP35 knockdown inhibits Ebola virus amplification and protects against lethal infection in mice. Antimicrob. Agents Chemother. 50, 984993.
  • Erikson, E., T. Adam, S. Schmidt, J. Lehmann-Koch, B. Over, C. Goffinet, C. Harter, I. Bekeredjian-Ding, S. Sertel, F. Lasitschka, and O. T. Keppler, 2011: In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc. Natl. Acad. Sci. U.S.A. 108, 1368813693.
  • Fabozzi, G., C. S. Nabel, M. A. Dolan, and N. J. Sullivan, 2011: Ebolavirus proteins suppress the effects of small interfering RNA by direct interaction with the mammalian RNA interference pathway. J. Virol. 85, 25122523.
  • Feng, Z., M. Cerveny, Z. Yan, and B. He, 2007: The VP35 protein of Ebola virus inhibits the antiviral effect mediated by double-stranded RNA-dependent protein kinase PKR. J. Virol. 81, 182192.
  • García, M. A., E. F. Meurs, and M. Esteban, 2007: The dsRNA protein kinase PKR: virus and cell control. Biochimie 89, 799811.
  • García-Sastre, A., and C. A. Biron, 2006: Type 1 interferons and the virus-host relationship: a lesson in detente. Science 312, 879882.
  • George, C. X., Z. Li, K. M. Okonski, A. M. Toth, Y. Wang, and C. E. Samuel, 2009: Tipping the balance: antagonism of PKR kinase and ADAR1 deaminase functions by virus gene products. J. Interferon Cytokine Res. 29, 477487.
  • Goffinet, C., I. Allespach, S. Homann, H. M. Tervo, A. Habermann, D. Rupp, L. Oberbremer, C. Kern, N. Tibroni, S. Welsch, J. Krijnse-Locker, G. Banting, H. G. Kräusslich, O. T. Fackler, and O. T. Keppler, 2009: HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5, 285297.
  • Goffinet, C., S. Homann, I. Ambiel, N. Tibroni, D. Rupp, O. T. Keppler, and O. T. Fackler, 2010: Antagonism of CD317 restriction of human immunodeficiency virus type 1 (HIV-1) particle release and depletion of CD317 are separable activities of HIV-1 Vpu. J. Virol. 84, 40894094.
  • Groseth, A., H. Feldmann, and J. E. Strong, 2007: The ecology of Ebola virus. Trends Microbiol. 15, 408416.
  • Gupta, R. K., P. Mlcochova, A. Pelchen-Matthews, S. J. Petit, G. Mattiuzzo, D. Pillay, Y. Takeuchi, M. Marsh, and G. J. Towers, 2009: Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U.S.A. 106, 2088920894.
  • Haasnoot, J., W. de Vries, E. J. Geutjes, M. Prins, P. de Haan, and B. Berkhout, 2007: The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathog. 3, e86.
  • Haller, O., P. Staeheli, and G. Kochs, 2007: Interferon-induced Mx proteins in antiviral host defense. Biochimie 89, 812818.
  • Hammonds, J., J. J. Wang, H. Yi, and P. Spearman, 2010: Immunoelectron microscopic evidence for Tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. PLoS Pathog. 6, e1000749.
  • Han, Z., H. Boshra, J. O. Sunyer, S. H. Zwiers, J. Paragas, and R. N. Harty, 2003: Biochemical and functional characterization of the Ebola virus VP24 protein: implications for a role in virus assembly and budding. J. Virol. 77, 17931800.
  • Hartlieb, B., and W. Weissenhorn, 2006: Filovirus assembly and budding. Virology 344, 6470.
  • Hartman, A. L., J. S. Towner, and S. T. Nichol, 2004: A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology 328, 177184.
  • Hartman, A. L., J. E. Dover, J. S. Towner, and S. T. Nichol, 2006: Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 80, 64306440.
  • Hartman, A. L., B. H. Bird, J. S. Towner, Z. A. Antoniadou, S. R. Zaki, and S. T. Nichol, 2008a: Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of Ebola virus. J. Virol. 82, 26992704.
  • Hartman, A. L., L. Ling, S. T. Nichol, and M. L. Hibberd, 2008b: Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J. Virol. 82, 53485358.
  • Hartman, A. L., J. S. Towner, and S. T. Nichol, 2010: Ebola and marburg hemorrhagic fever. Clin. Lab. Med. 30, 161177.
  • Hayman, D. T., P. Emmerich, M. Yu, L. F. Wang, R. Suu-Ire, A. R. Fooks, A. A. Cunningham, and J. L. Wood, 2010: Long-term survival of an urban fruit bat seropositive for Ebola and Lagos bat viruses. PLoS ONE 5, e11978.
  • Hoenen, T., A. Groseth, L. Kolesnikova, S. Theriault, H. Ebihara, B. Hartlieb, S. Bamberg, H. Feldmann, U. Ströher, and S. Becker, 2006: Infection of naive target cells with virus-like particles: implications for the function of Ebola virus VP24. J. Virol. 80, 72607264.
  • Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi, 2005: IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772777.
  • Huang, Y., L. Xu, Y. Sun, and G. J. Nabel, 2002: The assembly of Ebola virus nucleocapsid requires virion-associated proteins 35 and 24 and posttranslational modification of nucleoprotein. Mol. Cell 10, 307316.
  • Huang, I. C., C. C. Bailey, J. L. Weyer, S. R. Radoshitzky, M. M. Becker, J. J. Chiang, A. L. Brass, A. A. Ahmed, X. Chi, L. Dong, L. E. Longobardi, D. Boltz, J. H. Kuhn, S. J. Elledge, S. Bavari, M. R. Denison, H. Choe, and M. Farzan, 2011: Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 7, e1001258.
  • Jia, B., R. Serra-Moreno, W. Neidermyer, A. Rahmberg, J. Mackey, I. B. Fofana, W. E. Johnson, S. Westmoreland, and D. T. Evans, 2009: Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5, e1000429.
  • Jiang, D., J. M. Weidner, M. Qing, X. B. Pan, H. Guo, C. Xu, X. Zhang, A. Birk, J. Chang, P. Y. Shi, T. M. Block, and J. T. Guo, 2010: Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J. Virol. 84, 83328341.
  • Jin, H., Z. Yan, B. S. Prabhakar, Z. Feng, Y. Ma, D. Verpooten, B. Ganesh, and B. He, 2010: The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide. J. Gen. Virol. 91, 352361.
  • Jouvenet, N., S. J. Neil, M. Zhadina, T. Zang, Z. Kratovac, Y. Lee, M. McNatt, T. Hatziioannou, and P. D. Bieniasz, 2009: Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83, 18371844.
  • Kaletsky, R. L., J. R. Francica, C. Agrawal-Gamse, and P. Bates, 2009: Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 106, 28862891.
  • Kawaoka, Y., 2005: How Ebola virus infects cells. N. Engl. J. Med. 352, 26452646.
  • Kimberlin, C. R., Z. A. Bornholdt, S. Li, V. L. Woods Jr, I. J. MacRae, and E. O. Saphire, 2010: Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc. Natl. Acad. Sci. U.S.A. 107, 314319.
  • Kühl, A., C. Banning, A. Marzi, J. Votteler, I. Steffen, S. Bertram, I. Glowacka, A. Konrad, M. Stürzl, J. T. Guo, U. Schubert, H. Feldmann, G. Behrens, M. Schindler, and S. Pöhlmann, 2011a: The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin. J. Infect. Dis. 204 (Suppl. 3), S850S860.
  • Kühl, A., M. Hoffmann, M. A. Müller, V. J. Munster, M. Kiene, T. S. Tsegaye, G. Behrens, G. Herrler, H. Feldmann, C. Drosten, and S. Pöhlmann, 2011b: Comparative analysis of Ebola virus glycoprotein interactions with human and bat cells. J. Infect. Dis. 204 (Suppl. 3), S8409.
  • Kuhn, J. H., 2008: Filoviruses. A compendium of 40 years of epidemiological, clinical, and laboratory studies. Arch. Virol. Suppl. 20, 13360.
  • Kupzig, S., V. Korolchuk, R. Rollason, A. Sugden, A. Wilde, and G. Banting, 2003: Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4, 694709.
  • Le Tortorec, A., and S. J. Neil, 2009: Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83, 1196611978.
  • Lee, M. S., F. J. Lebeda, and M. A. Olson, 2009: Fold prediction of VP24 protein of Ebola and Marburg viruses using de novo fragment assembly. J. Struct. Biol. 167, 136144.
  • Leroy, E. M., B. Kumulungui, X. Pourrut, P. Rouquet, A. Hassanin, P. Yaba, A. Délicat, J. T. Paweska, J. P. Gonzalez, and R. Swanepoel, 2005: Fruit bats as reservoirs of Ebola virus. Nature 438, 575576.
  • Leung, D. W., N. D. Ginder, D. B. Fulton, J. Nix, C. F. Basler, R. B. Honzatko, and G. K. Amarasinghe, 2009: Structure of the Ebola VP35 interferon inhibitory domain. Proc. Natl. Acad. Sci. U.S.A. 106, 411416.
  • Leung, D. W., K. C. Prins, D. M. Borek, M. Farahbakhsh, J. M. Tufariello, P. Ramanan, J. C. Nix, L. A. Helgeson, Z. Otwinowski, R. B. Honzatko, C. F. Basler, and G. K. Amarasinghe, 2010: Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 17, 165172.
  • Licata, J. M., R. F. Johnson, Z. Han, and R. N. Harty, 2004: Contribution of Ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J. Virol. 78, 73447351.
  • Liu, S. Y., D. J. Sanchez, and G. Cheng, 2011: New developments in the induction and antiviral effectors of type I interferon. Curr. Opin. Immunol. 23, 5764.
  • Lopez, L. A., S. J. Yang, H. Hauser, C. M. Exline, K. G. Haworth, J. Oldenburg, and P. M. Cannon, 2010: Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 84, 72437255.
  • Lu, J., Q. Pan, L. Rong, W. He, S. L. Liu, and C. Liang, 2011: The IFITM proteins inhibit HIV-1 infection. J. Virol. 85, 21262137.
  • Mahanty, S., M. Gupta, J. Paragas, M. Bray, R. Ahmed, and P. E. Rollin, 2003: Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 312, 415424.
  • Mangeat, B., G. Gers-Huber, M. Lehmann, M. Zufferey, J. Luban, and V. Piguet, 2009: HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. PLoS Pathog. 5, e1000574.
  • Mansouri, M., K. Viswanathan, J. L. Douglas, J. Hines, J. Gustin, A. V. Moses, and K. Früh, 2009: Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi’s sarcoma-associated herpesvirus. J. Virol. 83, 96729681.
  • Mateo, M., S. P. Reid, L. W. Leung, C. F. Basler, and V. E. Volchkov, 2010: Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J. Virol. 84, 11691175.
  • McNatt, M. W., T. Zang, T. Hatziioannou, M. Bartlett, I. B. Fofana, W. E. Johnson, S. J. Neil, and P. D. Bieniasz, 2009: Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 5, e1000300.
  • Mehedi, M., D. Falzarano, J. Seebach, X. Hu, M. S. Carpenter, H. J. Schnittler, and H. Feldmann, 2011: A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J. Virol. 85, 54065414.
  • Mitchell, R. S., C. Katsura, M. A. Skasko, K. Fitzpatrick, D. Lau, A. Ruiz, E. B. Stephens, F. Margottin-Goguet, R. Benarous, and J. C. Guatelli, 2009: Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. PLoS Pathog. 5, e1000450.
  • Mühlberger, E., M. Weik, V. E. Volchkov, H. D. Klenk, and S. Becker, 1999: Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J. Virol. 73, 23332342.
  • Neil, S. J., T. Zang, and P. D. Bieniasz, 2008: Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature, 451, 425430.
  • NIAID, 2011: NIAID category A, B, and C priority pathogens. Available at: http://www.niaid.nih.gov/topics/biodefenserelated/biodefense/research/pages/cata.aspx (accessed on 10 August 2011).
  • Ono, A., and E. O. Freed, 2001: Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. U.S.A. 98, 1392513930.
  • Pardieu, C., R. Vigan, S. J. Wilson, A. Calvi, T. Zang, P. Bieniasz, P. Kellam, G. J. Towers, and S. J. Neil, 2010: The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin. PLoS Pathog. 6, e1000843.
  • Perez-Caballero, D., T. Zang, A. Ebrahimi, M. W. McNatt, D. A. Gregory, M. C. Johnson, and P. D. Bieniasz, 2009: Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139, 499511.
  • Prins, K. C., W. B. Cárdenas, and C. F. Basler, 2009: Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J. Virol. 83, 30693077.
  • Prins, K. C., J. M. Binning, R. S. Shabman, D. W. Leung, G. K. Amarasinghe, and C. F. Basler, 2010a: Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J. Virol. 84, 1058110591.
  • Prins, K. C., S. Delpeut, D. W. Leung, O. Reynard, V. A. Volchkova, S. P. Reid, P. Ramanan, W. B. Cárdenas, G. K. Amarasinghe, V. E. Volchkov, and C. F. Basler, 2010b: Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs. J. Virol. 84, 30043015.
  • Radoshitzky, S. R., L. Dong, X. Chi, J. C. Clester, C. Retterer, K. Spurgers, J. H. Kuhn, S. Sandwick, G. Ruthel, K. Kota, D. Boltz, T. Warren, P. J. Kranzusch, S. P. Whelan, and S. Bavari, 2010: Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 84, 1056910580.
  • Reid, S. P., W. B. Cárdenas, and C. F. Basler, 2005: Homo-oligomerization facilitates the interferon-antagonist activity of the ebolavirus VP35 protein. Virology, 341, 179189.
  • Reid, S. P., L. W. Leung, A. L. Hartman, O. Martinez, M. L. Shaw, C. Carbonnelle, V. E. Volchkov, S. T. Nichol, and C. F. Basler, 2006: Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80, 51565167.
  • Reid, S. P., C. Valmas, O. Martinez, F. M. Sanchez, and C. F. Basler, 2007: Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 81, 1346913477.
  • Sadler, A. J., and B. R. Williams, 2008: Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8, 559568.
  • Sakuma, T., T. Noda, S. Urata, Y. Kawaoka, and J. Yasuda, 2009: Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83, 23822385.
  • Sanchez, A., S. G. Trappier, B. W. Mahy, C. J. Peters, and S. T. Nichol, 1996: The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. Proc. Natl. Acad. Sci. U.S.A. 93, 36023607.
  • Sauter, D., M. Schindler, A. Specht, W. N. Landford, J. Münch, K. A. Kim, J. Votteler, U. Schubert, F. Bibollet-Ruche, B. F. Keele, J. Takehisa, Y. Ogando, C. Ochsenbauer, J. C. Kappes, A. Ayouba, M. Peeters, G. H. Learn, G. Shaw, P. M. Sharp, P. Bieniasz, B. H. Hahn, T. Hatziioannou, and F. Kirchhoff, 2009: Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 6, 409421.
  • Schindler, C., D. E. Levy, and T. Decker, 2007: JAK-STAT signaling: from interferons to cytokines. J. Biol. Chem. 282, 2005920063.
  • Schoggins, J. W., S. J. Wilson, M. Panis, M. Y. Murphy, C. T. Jones, P. Bieniasz, and C. M. Rice, 2011: A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472, 481485.
  • Schumann, M., T. Gantke, and E. Muhlberger, 2009: Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 83, 89938997.
  • Sekimoto, T., N. Imamoto, K. Nakajima, T. Hirano, and Y. Yoneda, 1997: Extracellular signal-dependent nuclear import of Stat1 is mediated by nuclear pore-targeting complex formation with NPI-1, but not Rch1. EMBO J. 16, 70677077.
  • Siegrist, F., M. Ebeling, and U. Certa, 2011: The small interferon-induced transmembrane genes and proteins. J. Interferon Cytokine Res. 31, 183197.
  • Simmons, G., D. N. Gosalia, A. J. Rennekamp, J. D. Reeves, S. L. Diamond, and P. Bates, 2005: Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U.S.A. 102, 1187611881.
  • Swanepoel, R., P. A. Leman, F. J. Burt, N. A. Zachariades, L. E. Braack, T. G. Ksiazek, P. E. Rollin, S. R. Zaki, and C. J. Peters, 1996: Experimental inoculation of plants and animals with Ebola virus. Emerg. Infect. Dis. 2, 321325.
  • Takada, A., C. Robison, H. Goto, A. Sanchez, K. G. Murti, M. A. Whitt, and Y. Kawaoka, 1997: A system for functional analysis of Ebola virus glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 94, 1476414769.
  • Towner, J. S., T. K. Sealy, M. L. Khristova, C. G. Albariño, S. Conlan, S. A. Reeder, P. L. Quan, W. I. Lipkin, R. Downing, J. W. Tappero, S. Okware, J. Lutwama, B. Bakamutumaho, J. Kayiwa, J. A. Comer, P. E. Rollin, T. G. Ksiazek, and S. T. Nichol, 2008: Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 4, e1000212.
  • Van Damme, N., D. Goff, C. Katsura, R. L. Jorgenson, R. Mitchell, M. C. Johnson, E. B. Stephens, and J. Guatelli, 2008: The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3, 245252.
  • Volchkov, V. E., S. Becker, V. A. Volchkova, V. A. Ternovoj, A. N. Kotov, S. V. Netesov, and H. D. Klenk, 1995: GP mRNA of Ebola virus is edited by the Ebola virus polymerase and by T7 and vaccinia virus polymerases. Virology 214, 421430.
  • Volchkov, V. E., H. Feldmann, V. A. Volchkova, and H. D. Klenk, 1998: Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc. Natl. Acad. Sci. U.S.A. 95, 57625767.
  • Volchkova, V. A., H. D. Klenk, and V. E. Volchkov, 1999: Delta-peptide is the carboxy-terminal cleavage fragment of the nonstructural small glycoprotein sGP of Ebola virus. Virology 265, 164171.
  • Wahl-Jensen, V. M., T. A. Afanasieva, J. Seebach, U. Ströher, H. Feldmann, and H. J. Schnittler, 2005: Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J. Virol. 79, 1044210450.
  • Watanabe, R., G. P. Leser, and R. A. Lamb, 2011: Influenza virus is not restricted by tetherin whereas influenza VLP production is restricted by tetherin. Virology 417(1), 5056.
  • Weidner, J. M., D. Jiang, X. B. Pan, J. Chang, T. M. Block, and J. T. Guo, 2010: Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J. Virol. 84, 1264612657.
  • Wool-Lewis, R. J., and P. Bates, 1998: Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. J. Virol. 72, 31553160.
  • Yondola, M. A., F. Fernandes, A. Belicha-Villanueva, M. Uccelini, Q. Gao, C. Carter, and P. Palese, 2011: Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J. Virol. 85, 24802491.
  • Yount, J. S., B. Moltedo, Y. Y. Yang, G. Charron, T. M. Moran, C. B. Lopéz, and H. C. Hang, 2010: Palmitoylome profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. Nat. Chem. Biol. 6, 610614.